INBX logo

Inhibrx Biosciences Inc.

INBX
Healthcare|Biotechnology|US
$84.52
+4.24 (+5.28%)
DCF Value
$0.74
Cash / Share
$8.51
Next Earnings Report
Nov 13, 2026
EPS est. -$2.45 · Revenue est. $1.9M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (4)

Jun 2027
Est. completion
P2Triple Negative Breast Cancer
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
NCT06353997n=12
Dec 2028
Est. completion
P1Ewing Sarcoma
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933n=411
Dec 2029
Est. completion
P2P3Head and Neck Squamous Cell Carcinoma (HNSCC)
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
NCT06295731n=450
Jul 2033
Est. completion
P1P2Solid Tumor
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766n=340

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Sep 2025
P2
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075

Recent Press Releases

Inhibrx Announces Participation in Upcoming Scientific Conferences
Oct 13, 2026 · PRNewsWire
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Sep 8, 2026 · PRNewsWire
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
Sep 4, 2026 · PRNewsWire
Inhibrx Reports Second Quarter 2026 Financial Results
Aug 13, 2026 · PRNewsWire

SEC Filings (64)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 28, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Sep 28, 20268-KMaterial eventDocumentIndex
Sep 8, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 3, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 16, 20268-KMaterial eventDocumentIndex
Jun 15, 20268-KMaterial eventDocumentIndex
Jun 3, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 11, 20268-KMaterial eventDocumentIndex
Apr 23, 2026ARSAnnual report to holdersDocumentIndex
Apr 23, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 23, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 21, 20268-KMaterial eventDocumentIndex
Mar 19, 20268-KMaterial eventDocumentIndex
Mar 19, 202610-KAnnual reportDocumentIndex
Feb 23, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 11, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 21, 2026SC 13GPassive 5%+ stakeDocumentIndex
Dec 16, 20258-KMaterial eventDocumentIndex
Nov 14, 20258-KMaterial eventDocumentIndex
Nov 14, 202510-QQuarterly reportDocumentIndex
Oct 23, 20258-KMaterial eventDocumentIndex
Oct 17, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 20258-KMaterial eventDocumentIndex
Aug 13, 202510-QQuarterly reportDocumentIndex
Jun 4, 2025EFFECTDocumentIndex
Jun 2, 2025POS AMDocumentIndex
May 28, 2025424B3Offering prospectusDocumentIndex
May 28, 20258-KMaterial eventDocumentIndex
May 14, 2025424B3Offering prospectusDocumentIndex
May 14, 20258-KMaterial eventDocumentIndex